CellCentric
PrivateLast Round
Series D
May 6, 2026
Est. Valuation
$900M
Total Funding Raised
$436.58M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
CellCentric is a biotechnology company that develops clinical-stage small-molecule inhibitors targeting p300/CBP for the treatment of multiple myeloma and other cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CellCentric Comparables
Compare CellCentric with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Karyopharm Therapeutics | 78% | |
| C4 Therapeutics | 74% | |
| Opna Bio | 74% |
CellCentric Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | May 6, 2026 | ||||
| Series C | May 19, 2025 | ||||
| Series B | Jul 24, 2024 | ||||
| VC Round | Sep 11, 2023 | ||||
| Convertible Debt | Jul 11, 2023 | ||||
VC Round | Jan 26, 2022 |
Key People
Founding team and executive leadership
CellCentric Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Avego Management | Series D, Series C |
| Forbion Capital Partners | Series C |
| RA Capital Management | Series D, Series C, Series B |
| Future Planet Capital Regional | Grant |
| Forbion | Series D, Series C |
| BrightEdge | Series C, Series B, VC Round |
| Morningside Ventures | VC Round, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 6, 2026
$220M round led by Venrock.
- Dec 19, 2025
Inobrodib enters Phase 3 trial for multiple myeloma and other cancers.
Recent news
Latest coverage and updates
- hiresSep 8, 2026
CellCentric Limited hired Paolo as Non-Executive Director on Sep 8th '26.
- hiresSep 8, 2026
CellCentric Limited hired Jason Cavalier as Chief Financial Officer on Sep 8th '26.
- hiresSep 8, 2026
CellCentric Limited hired Jason as Chief Financial Officer on Sep 8th '26.
CellCentric Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about CellCentric's valuation, stock price, and market status.
Is CellCentric a public or private company?
CellCentric is a private company.
What is the current stock price of CellCentric?
CellCentric is a private company with no public stock price. No recent secondary market data is available.
How much is CellCentric worth (valuation)?
CellCentric's valuation is estimated at $900.0M based on funding round data.
Can I buy CellCentric stock?
CellCentric shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was CellCentric's last funding round?
CellCentric's most recent funding round was Series D on May 6, 2026.
Who are the main investors in CellCentric?
Key investors in CellCentric include Forbion Capital Partners, RA Capital Management, Forbion, Nesta Impact Investments, Pfizer.
Will CellCentric IPO soon?
No public IPO plans have been announced for CellCentric.
How can I track CellCentric secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CellCentric's secondary market activity and sign up for updates.